Abstract: There has been a large increase in data on the genetic causes of iron accumulation. In addition, there is a growing body of literature on the significance of iron in liver biopsy specimens obtained for staging and grading chronic liver disease. In this review, the current literature is discussed with a focus on aspects that are most relevant to the practice of surgical pathology.
DEFINITIONS
There has been significant progress over the past several decades in understanding the causes and significance of iron accumulation in the liver. There are many excellent review articles on the molecular biology and the clinical management of iron overload in the liver. This update is designed to summarize the major advances and also to synthesize the current literature with a focus on relevance to surgical pathology.
In this review, we shall use the following terminology: the term "hemochromatosis" will indicate hepatic iron accumulation in the setting of a genetic mutation; the term "siderosis" will indicate hepatic iron accumulation without a genetic mutation; and the terms "primary" and "secondary" will be avoided. The term "genetic nonhemochromatotic iron overload" will be used for genetic disorders that lead to iron accumulation that primarily affects Kupffer cells and macrophages.
OVERVIEW OF NORMAL IRON METABOLISM
The normal adult body contains a total of 3 to 5 grams of iron (for comparison, a US nickel weighs 5 g). About 20 mg of iron is needed each day for normal physiological functions, but the majority of this daily need is met through recycling of damaged red blood cell. For this reason, only 1 to 2 mg per day of iron is needed in a healthy diet, though the Recommended Daily Allowance (RDA) is somewhat higher at 8 to 18 mg of iron.
Iron is absorbed in the small intestine from dietary sources and is important in a number of metabolic processes.
For example, heme synthesis, oxidative phosphorylation, and DNA synthesis, all require iron. Despite its importance, iron can be toxic to cells at high levels, in part through the generation of free oxygen radicals. The body has to tightly regulate iron levels to balance the need for iron with the need to avoid toxicity. The human body has no physiological way to excrete iron and whatever iron is absorbed in the small intestine has to be either used or stored. Thus, iron regulation tightly controls the absorption of iron from the small intestine. Additional controls regulate blood iron levels as well the uptake of iron by individual cells.
Major Proteins and Cells Involved in Iron Metabolism
There are many proteins and cells involved in iron metabolism, but the major ones are shown in Table 1 for quick reference. They work as an integrated network to regulate iron absorption and to regulate blood and cellular levels of iron.
Iron Absorption
Most iron is absorbed in the duodenum and proximal jejunum. Heme-iron is taken up by the enterocytes after disassociation from globin, whereas non-heme iron is first reduced from a ferric to a ferrous state and then transported across the cell membrane into the enterocytes by a protein called DMT-1, where the iron is first sequestered into the cytoplasm of enterocytes. Once iron is within the enterocytes, it can have several fates. If the body has sufficient iron stores, then the iron remains within the cytoplasm of the enterocytes. When the enterocyte eventually dies, the iron within the cell's cytoplasm is lost within the fecal stream; this is a major control mechanism to prevent iron overload (Fig. 1) . In contrast, if the body needs iron, then the iron is transported out of the enterocyte by ferroportin, with some help by accessory proteins including ceruloplasmin and hephaestin, and enters the blood stream where it is bound by transferrin and circulates within the blood (Fig. 1) . In healthy individuals, the blood contains much more transferrin protein than iron and the transferrin levels are approximately 30% saturated with iron. As blood iron levels increase, the excess transferrin proteins serve as a buffer that will bind excess iron to help prevent toxicity from too much free iron in the blood.
Getting Iron From the Blood Into Cells
Individual cells have mechanisms to determine if they have sufficient iron stores within their cytoplasm to meet their needs. If iron is needed, then the cells increase their expression of transferrin receptors. There are 2 transferrin receptors, named transferrin receptor 1 and transferrin receptor 2. Transferrin receptor 1 is present on the membrane of all nucleated cells, whereas receptor 2 is primarily found on hepatocytes and macrophages. These receptors import iron through receptor-mediated endocytosis. The HFE gene product interacts with transferrin receptor.
Iron Storage
If there is excess iron within the cells, it can be incorporated into ferritin molecules for storage, largely in hepatocytes and macrophages. Ferritin is produced principally by the liver and is found in the liver cytoplasm, where it can hold up to 4500 atoms of iron per ferritin protein complex. Ferritin is typically not visible on Perls' Prussian blue stain, but occasionally it can be seen as a diffuse blush of blue in the hepatocyte cytoplasm ( Fig. 2A) . The iron in ferritin can be rapidly accessed to meet physiological needs. If ferritin levels are excessive over a sufficiently long period of time, hemosiderin deposits can then develop.
Hemosiderin is granular and golden brown on hematoxylin and eosin (H&E) staining (Fig. 2B ) and is composed of iron and various proteins, principally degraded ferritin. Most of the metal in hemosiderin is iron, but also present are small amounts of copper and calcium. Hemosiderin has an identical H&E appearance in both genetic and nongenetic iron overload, but there are differences in the metallic as well as the organic components. 1 In contrast to ferritin, the iron in hemosiderin is not as readily available for biological needs.
In summation, there are 2 important reservoirs of iron that can both be tapped to keep iron levels in the blood at physiologically correct levels: (1) a short-term reservoir of iron stored within enterocytes and (2) a longer-term reservoir of iron stored as ferritin, principally in hepatocytes and macrophages. Both reservoirs have separate but integrated control mechanisms that serve to regulate iron flow into the blood. If they both are unable to meet the demands for iron, then anemia develops; if they have dysregulated (mutated) control mechanisms, then hemochromatosis can develop.
Control of Iron Release From Stores in the Enterocytes, Liver, and Macrophages
When blood iron levels are low, iron is released from the ferritin stored in enterocytes, hepatocytes, and macrophages. However, the release of iron from these 3 cell types is blocked when blood iron levels are adequate. Hepcidin is a major controller of iron metabolism 2, 3 : It blocks the release of iron from hepatocytes, macrophages, and enterocytes (Fig. 3) . When hepcidin levels are lowered, there is increased iron absorption from the gut and increased release of iron into the blood.
Hepcidin (encoded by HAMP) is an acute phase reactant produced by hepatocytes 4 and biliary epithelium.
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Because it is an acute phase reactant, hepcidin levels can be elevated in a variety of inflammatory and infectious conditions ( Table 2 ). The main physiological role of hepcidin in healthy individuals is to lower blood iron levels by blocking transfer of iron from enterocytes to the blood and by blocking the release of iron stores from the liver and macrophages into the blood. Hepcidin accomplishes this in part by causing the internalization and degradation of ferroportin, 6 the protein that transports iron out of cells into the blood. Ferroportin is the only known export protein for iron and without it the iron stays within the enterocytes, macrophages, and hepatocytes.
How Do Mutations Lead to Iron Accumulation?
Recent laboratory findings have uncovered a central role for hepcidin in hemochromatosis. 2 In fact, mutations that lead to hemochromatosis all lead to decreased hepcidin production or impaired hepcidin function, including mutations in HFE, HAMP, HJV, and TfR2.
7 These low levels of hepcidin gradually lead to excess iron absorption and deposition in the liver and other organs. Interestingly, to date, all mutations lead to a loss of hepcidin function and mutations that could potentially lead to an increase in hepcidin function have not been described. However, increased expression of hepcidin (with subsequent development of anemia) has been reported in a hepatic adenoma. 8 
MUTATIONS IN IRON-RELATED GENES
The major causes of genetic hemochromatosis are discussed individually below and summarized in Table 3 .
HFE Mutations
HFE mutations were first linked to hereditary hemochromatosis in 1996. 9 Since that time, over 37 mutations have been reported, 10 but C282Y and H63D mutations are by far the most numerically and clinically important. C282Y mutations are strongly linked to northern European (Table 4 ). In fact, the high mutational frequency has led to the suggestion that C282Y and H63D should be reclassified as polymorphisms.
Overall, the C282Y mutation accounts for 80% to 90% of genetic hemochromatosis cases, whereas H63D accounts for approximately 60% of the remaining cases. 12, 13 Other mutations, such as S65C, have also been linked to iron accumulation 12, 14 but the role of S65C in iron overloading is less clear. 15 Individuals with C282Y mutations are at much higher risk for iron accumulation than individuals with H63D mutations. Not surprisingly, C282Y homozygotes have greater risk for iron accumulation than do C282Y heterozygotes. An important point, however, is that there is great phenotypic variation, even in individuals homozygous for C282Y mutations. This is illustrated by a major population-based study from Australia, where 203 C282Y homozygous individuals were followed for 12 years. During this time, 28% of men and only 1% of women developed iron overload-related diseases. 16 Also of interest, a study of C282Y/H63D compound heterozygotes over the same 12-year interval found that only 1/82 men and none of 95 women developed iron-related disease. 17 The phenotypic variation is likely related to environmental factors, dietary factors, and other genetic polymorphisms. 18 Clearly female sex also has a strong protective effect. This is partly owing to physiological blood loss but other sex-associated polymorphisms appear relevant (reviewed in Wood et al). 19 
Causes of Death in HFE-related Hemochromatosis
Clinical follow-up studies have consistently identified liver decompensation from cirrhosis as well as hepatocellular carcinoma as leading causes of death in individuals who are untreated or incompletely treated for HFE hemochromatosis (Table 5) . [20] [21] [22] [23] However, there also is an increased risk for morbidity from heart failure and complications of diabetes. An increased risk for nonliver cancer has also been identified in some studies. 24, 25 Liver Transplantation for HFE Iron Overload Overall, genetic hemochromatosis is an uncommon indication for liver transplantation. An early study of liver transplant outcomes examined 5180 liver transplantations and reported that only 56 (1%) of the transplantations were for hemochromatosis. 26 This and other early studies reported lower survival rates for patients with genetic hemochromatosis compared with those transplanted for other causes of chronic liver disease. Major causes of mortality were infection, cardiac failure, and cancer. [26] [27] [28] However, a more recent study has shown great improvement over the last decade in the survival of individuals transplanted for hemochromatosis. 29 This increased survival likely reflects better patient selection and better pretransplant and posttransplant patient management. Despite this, cardiovascular disease continues to be an important cause of morbidity and mortality. 29 
FIGURE 1. Overview of iron absorption.
FIGURE 2. A, Ferritin is not visible on H&E but can sometimes be seen as a light blue blush on Perls iron stain. B, Hemosiderin has brown granular appearance on H&E stains. C, Hemosiderin can have a zone 1 pattern of hepatocellular deposition in cases with HFE mutations. However, this zone 1 pattern is often seen in cases without HFE mutation. D, Similarly, a pericanalicular patter of iron deposits is common with HFE mutations, but not diagnostic. E, Iron can be seen in the bile duct epithelium in cases with marked iron accumulation, including cases with HFE mutations. Cases without HFE mutations can also have bile duct iron deposits when there is marked iron accumulation. F, In contrast, iron deposits in proliferating bile ductules are common in areas of subacute parenchymal collapse and do not indicate iron overload conditions. G, Endothelial iron is often seen in the setting of Kupffer cell/macrophage iron as well as hepatic iron. Occasionally it is seen in isolation. Its clinical significance is currently unclear. H, Iron free foci should be carefully examined for cancer. The inset shows the background liver with marked iron accumulation. H&E indicates hematoxylin and eosin.
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Hemojuvelin Mutations (Usually Children/Early Onset)
Hemojuvelin mutations are the most common cause of juvenile hemochromatosis. 30, 31 Nevertheless, this remains a relatively rare disease. Hemojuvelin disease typically presents with impotence or amenorrhea and not with liver or joint disease. Cardiomyopathy is also common at presentation. In the liver, there can be marked hepatocellular iron overload. The disease typically runs a severe clinical course and can be rapidly progressive. 3 The G320V mutation is the most common and is found in 80% to 90% of cases of juvenile hemochromatosis. An I222N mutation has also been reported. In contrast to HFE mutations, the general population has a very low frequency of hemojuvelin mutations. For example, in a screen of 365 asymptomatic adults from Alabama, only 1 I222N mutation and no G320V mutations were found. 32 
Hepcidin (Usually Children/Early Onset)
This rare form of genetic iron overload has marked hepatocellular iron overload and typically runs a severe clinical course. Hypogonadism and cardiac disease are also prominent clinical manifestations.
Transferrin Receptor Gene 2 (Usually Adults/Late Onset)
This rare form of genetic iron overload has a variable clinical course but can have marked hepatocellular iron accumulation. Also of note, in the general asymptomatic adult population, polymorphisms in TRF2 are common and can lead to mild increases in blood iron levels without overt iron overload disease. 33 
DMT-1 Mutations (Usually Older Children)
This very rare disease has very few reported cases, so data are quite limited. 34, 35 Children present with severe microcytic anemia. Iron accumulation is primarily in hepatocytes but biopsies can be negative for iron in very young children.
Non-hemochromatotic Iron Overload Disease (ie, Mesenchymal Iron Accumulation)
Ferroportin disease is a classic example of hereditary iron overload where the iron accumulation can predominately affect Kupffer cells. 36 In contrast to the causes of hemochromatosis discussed above, all of which have elevated transferrin saturation levels early in the disease course, transferrin saturation levels in ferroportin disease do not become elevated until much later in the disease course. Ferroportin disease also stands out for its dominant inheritance pattern. 3 Of note, there is substantial phenotypic variability and the disease is divided into 2 subtypes with different disease manifestations. Histologically, iron deposits in Kupffer cells predominate over that of hepatocytes in subtype A, whereas hepatic iron is heavier than Kupffer cell iron in type B. A caveat is that the histological data on ferroportin disease are somewhat mixed and will only become more clear as larger case series are put together. Clinically, both types have milder disease than those with HFE mutations and, overall, type A ferroportin disease tends to be milder than type B. Several other rare forms of genetic non-hemochromatotic iron overload disorder are also listed in Table 3 .
Links Between HFE Mutations and Other Chronic Diseases
There are complex genetic, environmental, and dietary variables that determine the penetrance of disease in individuals with mutations in iron metabolism genes such as HFE. 18 Thus, it is not surprising that other chronic liver diseases can affect HFE penetrance and have been linked to iron overload and /or HFE mutations. Some diseases, such as alpha-1-antitrypsin deficiency and cryptogenic cirrhosis, can show marked iron accumulation with iron levels that equal those of genetic hemochromatosis. In fact, a recent study by Lam et al 14 showed that cirrhotic livers with both alpha-1-antitrypsin deficiency as well as marked iron overload were in fact enriched for HFE mutations. Whether this observation will be applicable to other diseases that are accompanied by marked iron overload is unclear and will require future studies, but it seems biologically plausible for HFE mutations to predispose to iron accumulation, and for that predisposition in turn to become increasingly penetrant in the setting of a second significant liver disease.
The relationship between disease severity and the presence of iron accumulation and/or the presence of HFE mutations has been investigated by numerous studies for many of the major chronic liver diseases, including chronic viral hepatitis C and B, alcohol-related liver disease, and nonalcoholic fatty liver disease (NAFLD). Although the data are substantially mixed, there is evidence to support an association between more severe disease and excess iron accumulation in all of these chronic liver diseases. The Hepcidin is a major regulator of iron and functions to lower blood iron levels by blocking iron absorption from the intestine, blocking release of iron from macrophages, and blocking release of iron from hepatocytes. 
Neonatal Hemochromatosis
Despite the term "hemochromatosis" in neonatal hemochromatosis, it is important to remember that neonatal hemochromatosis is fundamentally different than all the other iron-related diseases discussed above. Neonatal hemochromatosis is an alloimmune gestational disease where maternal antibodies cross the placenta and attack the fetal liver in utero. 37 The alloimmune target has not been clearly identified, but it is presumed to be an antigen on the hepatocyte cell surface. The newborn will typically have massive liver failure at birth or within the first few days of life. In many cases, there is late second-term or third-term fetal loss because the fetus did not survive the massive liver injury.
On biopsy of the liver (or on postmortem examination), the histology can range from massive liver necrosis with almost no residual hepatocytes, to a severely damaged liver with regenerative nodules that can give the liver a cirrhotic appearance. The residual hepatocytes in these cases are often inflamed, cholestatic, and may show giant cell transformation. An iron stain will typically show hepatic iron accumulation with course granules of iron, qualitatively similar to that seen in adult hemochromatosis, whereas the Kupffer cells generally have little iron accumulation. As an important caveat, the histological findings have not been described in many cases and it seems likely that there is more histological variation than is currently reported. Another clue to the diagnosis of neonatal hemochromatosis can be very high serum alphafetoprotein levels, which are typically greater than 100,000 ng/mL and can be as high as 800,000 ng/mL (as a reminder, the healthy neonate typically has values less than 80,000 ng/mL).
Of note, extrahepatic iron deposits are required to confidently make this diagnosis. The best places to look are (in approximate order): acini of the pancreas, myocardium, thyroid, minor salivary glands, Brunner glands, pancreas islets, stomach, and chondrocytes. 37 Lip biopsies can be helpful 38 but often are not deep enough to get the glands needed to look for iron accumulation and thus are often not informative. The bone marrow and spleen are not good places to look as they often will not have increased iron. Also, if most of the hepatocytes have been destroyed, then there may not be much iron in the liver biopsy.
The prognosis is poor unless the disease is quickly recognized. Although data are limited, for those children who do survive, there does not seem to be any significant medical sequelae.
If an infant is affected by this disease, there is about a 75% chance that subsequent pregnancies in the mother will be likewise affected, so this is an important disease to diagnose.
Treatment of affected infants revolves around supportive care and removing the maternal antibody through plasmapharesis. Prevention for subsequent pregnancies is approached by treatment during gestation with intravenous immunoglobulin that is typically given from about the 18th week of gestation until delivery.
More to Come
There remain a substantial proportion of cases of hepatic iron overload that do not appear to have the mutations described above. This seems to be particularly true for non-white populations. For example, in a study from Brazil, one-third of cases with marked iron overload did not have the typical mutations discussed above. 39 Similarly, iron 
DETECTION OF IRON IN THE LIVER Iron Stains
The major histochemical stain used to detect iron in the liver is Perls' Prussian blue, a stain named after Max Perls, a German pathologist. The basic chemistry of Perls' Prussian blue is that iron in the ferric state will react with hydrochloric acid to form ferric ferrocyanide, an insoluble blue compound (Prussian blue) that can be seen histologically. The distribution and density of blue staining correlates, albeit imperfectly, with tissue iron concentrations. The stain is not as sensitive for very low levels of iron but is easy to perform and reproducible.
Ferritin
Normally no ferritin will be seen. However, in cases of elevated serum ferritin levels, ferritin may be seen as a light, diffuse, blue blush of the hepatocyte or Kupffer cell cytoplasm ( Fig. 2A) .
Hemosiderin
Hemosiderin can be seen as brown granular deposits on H&E stains (Fig. 2B) and as a bright blue granular staining on iron stain. Residual brown granular material is often seen on iron stain and represents lipofuschin in most cases.
Iron Grading Systems
Many iron grading systems have been proposed over the years. They vary in their approach, but all seek to provide semi-quantitative data on the extent of iron accumulation. Some systems are based on the zonation of iron distribution, some on the lowest magnification that discernable granules can be seen, some on the percent of hepatocytes positive for iron. The system by Deugnier and Turlin 41 has the advantage of having been validated, but it is too complex to be readily adopted for routine diagnostic use.
Is one system clearly the best? Probably not. I personally use a schema (Table 6 ) based on the percent of hepatocytes positive for iron, similar to that described by LeSage et al. 42 For diagnostic cases, I include the descriptor (eg, "mild," "moderate," etc.) in the pathology report but do not routinely provide the corresponding numerical grade. I believe that this simple-to-use classification system provides sufficient clinical information for patient care. But there are many reasonable alternatives to consider if you prefer a different approach. A modified Scheuer system (shown in Table 7 ) is also a very useful and popular system. If employed, separate numbers should be given for hepatocellular and the reticuloendothelial iron.
Remember that using a numerical system does not make a diagnostic pathology report more scientific nor does it make it more accurate, as the numbers act essentially as synonyms for words. In contrast, using a numerical system is important in research studies, as it allows statistical comparison of groups.
Quantitative Measurement of Hepatic Iron Concentrations
Hepatic iron concentrations measured in fresh liver tissues or in paraffin-embedded tissues are equivalent. 43 Thus, paraffin-embedded tissues are preferred because it allows direct visualization of the tissue and assures the tissue is representative. This prevents submission of tissue that is largely composed of collapsed/fibrotic stroma or a nodule that is either unusually high or low in stainable iron compared with the rest of the tissue.
The normal adult liver has between 10 and 36 mmol iron/g dry weight of liver. As a frame or reference, excess iron accumulation has been classified as mild (up to 150 mmol iron/g dry weight of liver), moderate (151 to 300), and marked (>301). 41 
Hepatic Iron Index
Historically, the hepatic iron index was calculated as an aide to interpreting quantitative tissue iron levels. The hepatic iron index adjusts the total iron concentration for age, based on the observation that hepatic iron concentrations tend to increase steadily with age in individuals with genetic hemochromatosis, but not in individuals with "secondary" iron overload. A hepatic iron index greater than 1.9 was interpreted as consistent with genetic hemochromatosis. Given the advances in understanding the causes of hemochromatosis and the readily available genetic testing for HFE mutations, the diagnostic role for the hepatic iron index is largely gone. However, quantitative iron levels can still be useful in managing individuals on iron depletion therapy, regardless of the underlying cause of disease.
Noninvasive Measurements of Hepatic Iron
Once a diagnosis is established, imaging studies can be useful to manage patients on iron depletion therapy. Biopsies continue to be important in determining the fibrosis stage, identify other disease processes, and evaluating mass lesions. For studies, I also record the zonal pattern of iron and whether the distribution is homogenous. For studies, I also record endothelial iron and portal macrophage iron separately. 
HISTOLOGICAL FINDINGS
In genetic hemochromatosis, iron classically accumulates first within zone 1 hepatocytes (Fig. 2C) . A clear gradient in the amount of iron between zone 1 and zone 3 hepatocytes can often be seen, even with advanced iron accumulation. In addition, the iron distribution often has a distinctive clustering around the bile canaliculi (Fig. 2D) . However, a zone 1 distribution of iron can be seen in other non-hemochromatosis conditions and a diagnosis of hemochromatosis should not be based on recognizing a zonal pattern alone. On the basis of the currently available data, it seems most likely that the zone 1 predominate pattern of iron deposition reflects dysregulation of hepcidin, but this could be either through mutations or through reduced hepcidin production from other causes. It is generally thought that injury and death of hepatocytes will lead over time to a redistribution of iron into Kupffer cells and portal macrophages. In practice, even mild hepatocellular iron is often accompanied by mild Kupffer cell iron.
Iron can also be deposited in the epithelium of the bile duct proper (Fig. 2E) . At times, this finding has been interpreted as being highly suggestive or even diagnostic of HFE mutations. In my experience, this pattern of iron deposition can also be seen in cases that have marked iron overload but that lack HFE mutations, so caution is warranted to avoid over interpreting this finding. However, there is very little data that examines this specific point.
In addition, iron is commonly seen in proliferating bile ductules in areas of subacute parenchymal collapse in cirrhotic or noncirrhotic livers (Fig. 2F ). This finding is common and has no association with hemochromatosis.
With iron overload owing to transfusion-dependent anemias and similar causes, iron is classically first deposited in Kupffer cells and with time there is involvement of the hepatocytes. However, in practice most cases show a mixed hepatocellular and Kupffer cell iron staining pattern.
Iron can also be seen in some cases either exclusively in portal endothelial cells (Fig. 2G ) or in a combination of endothelial, hepatocyte, and Kupffer cell iron accumulation. There has not been any specific linkage of endothelial iron accumulation to a disease process or genetic mutation at this time, but it would not be surprising if this changes in the future. Only a few studies have looked at the biology or significance of endothelial iron deposits. In 1 study, endothelial iron positivity was linked to decreased interferon response in individuals with chronic hepatitis C infection. 44 
CLINICOPATHOLOGICAL SIGNIFICANCE OF IRON OVERLOAD Iron in Explanted Livers
Iron can accumulate in cirrhotic livers with many different underlying causes of disease. In a classic study, Ludwig et al, 45 studied iron levels in 447 liver explants. Iron stains were positive in 100% of hereditary hemochromatosis cases, 65% of cases of cryptogenic cirrhosis, 63% of alcohol cirrhosis cases, 65% of chronic hepatitis B cases, 56% of alpha-1-antitrypsin deficiency cases, 43% of chronic hepatitis C cases, 10% of primary biliary cirrhosis cases, and 7% of primary sclerosing cholangitis cases.
In this same study, the number of cases with a hepatic iron index of greater than 1.9, that is, marked iron overload, were as follows: hereditary hemochromatosis (100%), alpha-1-antitrypsin deficiency (28%), cryptogenic cirrhosis (19%), alcohol cirrhosis (14%), chronic hepatitis B cirrhosis (18%), chronic hepatitis C cirrhosis (7%), primary biliary cirrhosis (1%), and cirrhosis from primary sclerosing cholangitis (1%). One important take-home message from these data is that 20% or more of cirrhotic livers from alpha-1-antitrypsin deficiency or cryptogenic cirrhotic livers can have hepatic iron indexes greater than 1.9. Another important observation is that biliary cirrhosis is only rarely associated with iron overload.
Iron in the explanted liver is clinically relevant. An important study by Kowdley et al 46 found that patients with significant hepatic iron accumulation had decreased survival after transplantation regardless of whether they had an HFE mutation. The reason(s) for this are unclear, but the major causes of death in this and similar studies were heart failure and infection. Even without HFE mutations, marked iron in the explanted liver is clinically relevant. Fenton et al 47 reported a set of cases with marked iron accumulation in the liver and heart, but without HFE mutations. This cohort of cases had cardiac iron deposits and significant heart failure. Others have also reported that non ÀHFE-related cardiac iron overload can occur in the liver transplant population. 48 In terms of gross pathology, any foci with decreased iron deposition (even smaller subcentimeter foci) should be sampled to evaluate for carcinoma (Fig. 2H) . These "ironfree foci" are often associated with dysplastic nodules or with frank carcinoma.
Iron in Donor Liver Biopsies
There is relatively little data on the clinical relevance of iron positivity in donor livers. In one interesting study, iron was found in 49/284 (17%) of donor biopsies and was occasionally at moderate levels, but overall did not impact survival outcomes. 49 Another study of living donors found increased iron in 8% of liver biopsies. 50 A third study looked at the significance of donor iron in terms of subsequent fibrosis progression in individuals transplanted for chronic hepatitis C virus (HCV). They found a link between female sex, pretransplant iron content, and risk for fibrosis progression. 51 Inadvertent transplantation of individuals with marked iron overload has also been reported, 52 but the number of cases is too small to draw conclusions on the effect of the iron on the posttransplant course.
Iron in Liver Tissues With Chronic Hepatitis C Virus Infection
Iron deposits, including both hepatocellular as well as reticuloendothelial iron, are seen in a median of approximately 30% of liver biopsies performed to stage and grade chronic HCV, with a reported range of 5% to 48%. [53] [54] [55] [56] [57] [58] The wide range presumably reflects differences in sex, viral genotypes, and the proportion of cirrhotics in the cohort. In the majority of cases, the iron deposits are mild, occasionally moderate, and only very rarely severe.
A large body of literature has investigated the significance of HFE mutations in chronic HCV. Unfortunately, the literature remains substantially mixed on the key question of whether HFE mutations increase the risk for fibrosis progression. This current state of confusion likely reflects the many different study populations, study designs, as well as variable penetration of genetic hemochromatosis. Also, many studies do not adequately control for potentially confounding variables such as sex, viral genotypes, duration of HCV infection, etc. For example, genotype 3 infection has been linked to more hepatocellular iron than other genotypes. 56 Nevertheless, a reasonable way to synthesize the data is as follows: (1) individuals with chronic HCV do not have an increased risk for HFE mutations 53, [59] [60] [61] ; (2) once an individual has chronic HCV infection, HFE mutations may increase the rate of fibrosis progression. 62 In this regard, HFE mutations are associated with higher fibrosis stages in many 53, [59] [60] [61] [62] [63] [64] but not all studies. 54, 55 Overall, C282Y alleles seem to have a stronger risk for fibrosis than H63D alleles. 62 With a sufficiently long duration of chronic HCV infection, the risk of cirrhosis is high regardless of HFE mutational status and the effect of HFE mutations may be harder to discern. 62 Interestingly, HFE mutations have also been linked to increased inflammation on liver biopsy in some studies. 60, 61 The reasons for this are not clear. Also of note, despite the links between HFE mutations and fibrosis, HFE mutation status is often not associated with increased iron deposits by histochemical analysis. 55, 60, 61 There are contradictory results, however. As an example, H63D mutations, but not C282Y mutations, were associated with increased hepatic iron concentrations in 1 study. 62 For those individuals who have mild to moderate iron deposits with chronic HCV, but who lack HFE mutations, the data are just as muddled and the same "take-home message" as above appears to be relevant: there seems to be either no role or a very limited role for minimal or mild iron on a liver biopsy in terms of predicting fibrosis progression; however, for moderate or greater iron levels, there is likely a role. The finer details of fibrosis risk with iron deposition will require longitudinal data from paired biopsy studies.
The results of iron studies in the setting of chronic hepatitis B are broadly similar to that discussed for chronic hepatitis C. Iron is present in about a third of biopsy specimens, deposits are mainly mild, and are associated with higher stages of fibrosis but not HFE mutational status. 65 
Iron in Nonalcoholic Fatty Liver Disease
Hepatic iron deposition in NAFLD is common, with approximately 30% to 40% of liver biopsies showing iron accumulation. As with chronic viral hepatitis, in most cases the siderosis is mild and may involve either or both of the hepatic and Kupffer cell compartments. Moderate iron accumulation is much less common and marked iron accumulation is rare. The role of iron in fibrosis progression is even less clear than with chronic HCV. In one of the first studies to address this question, George et al found that increased histological iron was associated with increased fibrosis. 66 However, several other studies have not replicated this finding. 40, 41 A major study from the NASH-CRN found that reticuloendothelial iron, but not hepatocellular iron, was associated with increased fibrosis. 67 It remains unclear, however, whether this reticuloendothelial pattern of iron is promoting fibrosis or is instead caused by fibrosis. The biology of iron and fatty liver disease is further complicated because many individuals with fatty liver disease are relatively copper deficient, a state that reduces iron mobilization from hepatocytes. 68 The association of fatty liver and iron has been recently reviewed in detail by Sumida et al. 69 
Iron Overload and Liver Carcinoma
There is a high risk for hepatocellular carcinoma in individuals with genetic hemochromatosis and marked iron accumulation. The risk is greatest in those with cirrhosis, but hepatocellular carcinomas can occasionally arise in noncirrhotic livers, 70 including those with nonÀ HFE-related iron overload. 71 The risk was previously estimated to be as high as 200-fold, but more recent data suggests a lower, but still elevated, risk. 72 Precursor lesions include iron-free foci (Fig. 2G) . Most liver carcinomas in genetic hemochromatosis are hepatocellular carcinomas, but intrahepatic cholangiocarcinomas have also been reported. 73 In the setting of hepatitis C-related cirrhosis, there is an increased risk for hepatocellular carcinoma in livers that also have increased iron and long-term phlebotomy can reduce that risk. 74 In fact, the increased hepatocellular carcinoma risk in livers with iron appears to be broadly true regardless of the underlying cause of liver disease. In a massive study of over 5000 explanted livers, histological iron deposits were associated with an increased risk for hepatocellular carcinoma, even after adjusting for underlying liver disease. 75 
ACQUIRED IRON OVERLOAD
The classic description in the diseases discussed below is that of an exclusive or predominant Kupffer cell or macrophage pattern of iron deposition, but in actual practice a mixed pattern is commonly seen.
Hematological Disorders
In routine surgical pathology practice, it is fairly common to see hepatic siderosis in liver biopsies of patients with various hematological disorders, including sickle cell disease, thalessemia, etc. Liver biopsies in individuals with bone marrow transplants also commonly show excess iron accumulation.
Anemia of Chronic Disease
As hepcidin is an acute phase reactant, chronic inflammatory conditions can lead to mild siderosis that involves primarily Kupffer cells and to lesser extent hepatic iron accumulation.
Excess Iron Intake
Hepatic siderosis secondary to excess dietary intake is unusual, but rare cases do occur. Almost all such cases are seen in the setting of dietary/vitamin supplements. It is much more common to see mild siderosis in individuals who have had multiple blood transfusions.
SUMMARY
Many new mutations have been reported that lead to iron overload. They all have a shared mechanism through their impact on the levels of hepcidin. Hepcidin blocks iron absorption from the gut and blocks iron release from hepatocytes and macrophages/Kupffer cells. Individuals with genetic hemochromatosis have an increased risk for hepatocellular carcinoma, cholangiocarcinoma, and other nonliver malignancies. The role of HFE mutations in disease progression in chronic HCV and NAFLD is controversial: there seems overall to be a modest effect on fibrosis progression.
In surgical pathology, it is important to report the histological iron status in liver explants because marked iron overload in an explanted liver can be clinically important, even if HFE mutations are negative. Neonatal hemochromatosis is a critical diagnosis to make because it has substantial clinical relevance. Remember that you have to find iron outside of the liver to make the diagnosis.
In HFE-related disease, iron is deposited primarily in hepatocytes. Classic findings include a zone 1 distribution of iron deposits, as well as a pericanalicular pattern of iron deposits within the hepatocyte cytoplasm. Iron deposits in bile duct epithelial cells can also be seen. However, HFE genetic testing is needed to establish a diagnosis.
FREQUENTLY ASKED QUESTIONS ABOUT IRON
For a biopsy performed to stage and grade chronic viral hepatitis, what is the significance of iron on the iron stain?
A. The data on this question are quite mixed. Nevertheless, a reasonable distillation of the data is as follows: iron accumulation most likely has a small but measurable impact on fibrosis progression. However, other known risk factors for fibrosis progression, such as viral genotype, duration of infection, sex, etc., seem to have a stronger and more consistent impact on fibrosis than do mild iron accumulation. The risk for fibrosis progression and iron accumulation can be further stratified by the extent of iron accumulation, with marked iron having the greatest risk.
I have a liver biopsy where only iron is present in endothelial cells. What does this mean?
A. This pattern can be seen in a small proportion of cases, especially if iron stains are carefully examined at higher magnifications. There is no established clinical significance at this time.
Is an iron stain necessary as part of the "standard of care" for evaluating a liver biopsy?
A. I am aware of no evidence-based data on this point. I do a routine iron stain in my practice. I suspect that most pathology practices also include an iron stain as part of the routine evaluation of liver biopsies. It seems likely that an approach based on ordering iron stains after examining the H&E stain would be unlikely to miss cases with moderate or marked iron accumulation. Many cases with minimal or mild iron would be missed I suspect, but as the clinical relevance of these lower grades of iron is not well established, it would seem unlikely to materially impact patient care.
In an explanted liver, what is the significance of findings moderate or marked grades of hepatocellular iron in the situation where there is already a known cause of the liver disease, such as chronic hepatitis C?
A. Moderate or marked iron accumulation carries an increased risk of having an HFE mutation. However, many cases with marked iron, including some with bile duct epithelial iron accumulation, will not have HFE genetic mutations. Because of this, genetic testing is required if the patient/clinical team wants to determine the status of the HFE gene-you cannot reliably do this based on histology alone.
Some patients with marked iron accumulation in their explanted livers can also have systemic iron overloading, even if HFE mutational studies are negative. These individuals have an increased risk of cardiac iron deposition and some can develop significant cardiac disease posttransplantation.
The iron stain shows a diffuse light cytoplasmic staining of the hepatocytes. What does this mean?
A. This pattern is typical of ferritin and can be seen in some patients with elevated serum ferritin levels. Ferritin can also be seen in macrophages in many cases.
Do I need to formally grade the iron in liver specimens in routine practice of surgical pathology?
A. It is prudent patient care to provide information on the amount of iron accumulation in the hepatocellular and Kupffer cell compartments. The information should be sufficiently detailed to be clinically actionable when appropriate. A description is sufficient for this purpose and there are no data to support an additional need to provide a formal number derived from a specific scoring system.
Nevertheless, if the pathologist or clinicians prefer a formal numerical assessment, that is fine. However, sufficient scoring system detail should then be provided to allow a reader of the report to determine what the numbers mean (and should be in the body of the report; a statement that the grading system is "on file" or "available on request" is suboptimal). As an example, a statement of the sort "iron grade 2+" is in itself fairly useless and is strongly discouraged as neither the magnitude of the scale nor the location of the iron is apparent from this statement.
What is the best grading system for evaluating histological iron accumulation?
A. There are many adequate grading systems. They can be very useful in research studies and the specific system can be chosen based on the goals of the study. Please see Tables 6 and 7 for 2 useful approaches.
Does iron in the bile duct epithelium have special significance?
A. Iron in the bile duct epithelium is typically a marker of heavy iron accumulation, but it is not diagnostic for HFE mutations.
Does iron in bile ductules have special significance? Iron in proliferating bile ductules can be seen in areas of parenchymal collapse, even in livers with only mild iron accumulation and does not indicate HFE mutations are present.
I'm worried about missing one of the newer iron overload conditions. Are there any clinical and or histological clues that should cause me to consider one of these conditions?
Neonatal hemochromatosis should be considered in any biopsy or autopsy of a neonate or stillbirth with marked liver injury/necrosis. Often times, there will also be clinical history of previous late-term pregnancy losses. Iron in other organs should also prompt a consideration of this disease.
Age is an important clue for juvenile hemochromatosis. Iron accumulation in the young, especially with moderate or greater levels of iron, should prompt a note to ensure the clinicians are aware that there is excess iron. For those times that clinical history is available, a history of heart failure, impotence, or amenorrhea in the young can also be clues to juvenile hemochromatosis.
For ferroportin disease, an important clue is the pattern of Kupffer cell iron deposits along with clumpy sideronecrotic deposits of iron in an individual with normal ferritin levels.
Can I confidently diagnose genetic hemochromatosis on a liver biopsy?
A. No. However, moderate to marked iron accumulation in a noncirrhotic liver would suggest genetic hemochromatosis.
When should I comment in the surgical pathology report about the possibility of genetic hemochromatosis?
A. When there is moderate to marked hepatocellular iron in a noncirrhotic liver, I add a comment to my report that the iron accumulation may represent genetic hemochromatosis. Lower levels of iron could also in theory indicate hemochromatosis, but when there is another disease process such as hepatitis, alcohol-related liver disease, etc., mild iron may reflect nongenetic-based disruption of hepcidin. In these cases, I do not add a special note and only report out the iron stain.
In cirrhotic livers, I make a similar comment when there is marked hepatocellular iron accumulation. In biliary cirrhotics, I will also add a comment when the iron levels are in the moderate range.
